Two years safety and efficacy of tenofovir disoproxil fumarate (TDF) in patients with HBV-induced cirrhosis

被引：0
|
作者：
Strasser, S. I.
Gane, E. J.
Weilert, F.
Sievert, W.
George, J.
Crawford, D.
Ngu, M. C.
Heathcote, E. J.
Marcellin, P.
Sorbel, J.
Rousseau, F.
机构：
[1] Royal Prince Alfred Hosp, AW Morrow GE & Liver Ctr, Sydney, NSW, Australia
[2] Middlemore Hosp, Dept Gastroenterol, Manukau City, New Zealand
[3] Waikato Hosp, Hamilton, New Zealand
[4] Monash Med Ctr, Clayton, Vic, Australia
[5] Westmead Hosp, Storr Liver Unit, Univ Sydney, Westmead, NSW, Australia
[6] Princess Alexandra Hosp, Dept Gastroenterol & Hepatol, Woolloongabba, Qld, Australia
[7] Concord Repatriat Gen Hosp, Dept Gastroenterol, Concord, NSW, Australia
[8] Univ Toronto, Dept Gastroenterol, Toronto, ON M5S 1A1, Canada
[9] Univ Paris, Clichy, France
[10] Gilead Sci Inc, Durham, NC USA
来源：
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY | 2009年 / 24卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：A309 / A309
页数：1
相关论文
共 50 条
  • [1] TWO YEARS SAFETY AND EFFICACY OF TENOFOVIR DISOPROXIL FUMARATE (TDF) IN PATIENTS WITH HBV-INDUCED CIRRHOSIS
    Buti, M.
    Hadziyannis, S.
    Mathurin, P.
    Urbanek, P.
    Sherman, M.
    Strasser, S.
    Wang, C.
    Petersen, J.
    Heathcote, E. J.
    Marcellin, P.
    Sorbel, J.
    Mondou, E.
    Anderson, J.
    Rousseau, F.
    JOURNAL OF HEPATOLOGY, 2009, 50 : S10 - S11
  • [2] Two Years Safety and Efficacy of Tenofovir Disoproxil Fumarate (TDF) in Patients with HBV-Induced Cirrhosis
    Buti, Maria
    Hadziyannis, Stephanos J.
    Mathurin, Philippe
    Urbanek, Petr
    Sherman, Morris
    Strasser, Simone I.
    Wang, Chia C.
    Petersen, Joerg
    Heathcote, Jenny
    Marcellin, Patrick
    Sorbel, Jeff
    Mondou, Elsa
    Anderson, Jane
    Rousseau, Franck
    GASTROENTEROLOGY, 2009, 136 (05) : A865 - A866
  • [3] EFFICACY AND SAFETY OF TENOFOVIR ALAFENAMIDE (TAF) AT 96 WEEKS IN CHRONIC HBV (CHB) PATIENTS WITH RISK FACTORS FOR USE OF TENOFOVIR DISOPROXIL FUMARATE (TDF)
    Chan, Henry Lik-Yuen
    Buti, Maria
    Flisiak, Robert
    Ryder, Stephen
    Streinu-Cercel, Adrian
    Flaherty, John F.
    Gaggar, Anuj
    Mo, Shuyuan
    Subramanian, G. Mani
    Zoulim, Fabrian
    Andreone, Pietro
    Marcellin, Patrick
    GUT, 2018, 67 : A97 - A97
  • [4] 1 YEAR SAFETY AND EFFICACY DATA IN CHRONIC HBV PATIENTS WITH RISK FACTORS FOR TENOFOVIR DISOPROXIL FUMARATE (TDF) AFTER SWITCHING FROM TDF TO TENOFOVIR ALAFENAMIDE (TAF)
    Pan, Calvin Q.
    Gane, Edward
    Seto, Wai-Kay
    Janssen, Harry L.
    Caruntu, Florin
    Kim, Hyung Joon
    Abdurakhmanov, Dzhamal
    Nishiguchi, Shuhei
    Bae, Ho
    Mo, Shuyuan
    Suri, Vithika
    Gaggar, Anuj
    Flaherty, John F.
    Kao, Jia-Horng
    Brunetto, Maurizia Rossana
    Buti, Maria
    GASTROENTEROLOGY, 2018, 154 (06) : S1132 - S1133
  • [5] Efficacy and Safety of Tenofovir Alafenamide (TAF) at 96 Weeks in Chronic HBV (CHB) Patients with Risk Factors for Use of Tenofovir Disoproxil Fumarate (TDF)
    Buti, Maria
    Stepanova, Tatjana
    Celen, Mustafa K.
    Flisiak, Robert
    Ryder, Stephen D.
    Streinu-Cercel, Adrian
    Gurel, Selim
    Flaherty, John F.
    Gaggar, Anuj
    Suri, Vithika
    Mo, Shuyuan
    Subramanian, Mani
    Nurmukhametova, Elena
    Zoulim, Fabien
    Andreone, Pietro
    Marcellin, Patrick
    HEPATOLOGY, 2017, 66 : 488A - 488A
  • [6] SAFETY AND EFFICACY AT 48 WEEKS AFTER SWITCHING FROM TENOFOVIR DISOPROXIL FUMARATE (TDF) TO TENOFOVIR ALAFENAMIDE (TAF) IN CHRONIC HBV PATIENTS WITH RISK FACTORS FOR TDF USE
    Buti, Maria
    Lampertico, Pietro
    Lim, Young-Suk
    Agarwal, Kosh
    Fung, Scott K.
    Tsang, Owen
    Elkhashab, Magdy
    Kao, Jia-Horng
    Luis Calleja, Jose
    Khalili, Mandana
    Ravendhran, Natarajan
    Tan, Susanna
    Flaherty, John F.
    Gaggar, Anuj
    Lau, Audrey H.
    Wu, George
    Hann, Hie-Won L.
    Pan, Calvin
    Kim, Hyung Joon
    Kennedy, Patrick T. F.
    Chan, Henry Lik Yuen
    HEPATOLOGY, 2019, 70 : 301A - 301A
  • [7] Safety and efficacy at 1 year after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in chronic HBV patients with risk factors for TDF use
    Janssen, H.
    Gane, E.
    Seto, W-K
    Caruntu, F. A.
    Kim, H. J.
    Abdurakhmanov, D.
    Nishiguchi, S.
    Horban, A.
    Bae, H.
    Mo, S.
    Suri, V.
    Gaggar, A.
    Flaherty, J.
    Kao, J-H
    Brunetto, M.
    Ferret, M. B.
    JOURNAL OF VIRAL HEPATITIS, 2018, 25 : 27 - 27
  • [8] Safety and Efficacy at 1 Year after Switching from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in Chronic HBV Patients with Risk Factors for TDF Use
    Gane, Edward
    Seto, Wai Kay
    Janssen, Harry L. A.
    Caruntu, Florin A.
    Kim, Hyung Joon
    Abdurakhmanov, Dzhamal
    Nishiguchi, Shuhei
    Horban, Andrzej
    Bae, Ho
    Flaherty, John F.
    Gaggar, Anuj
    Suri, Vithika
    Oberle, Corinna
    Mo, Shuyuan
    Subramanian, G. Mani
    Kao, Jia-Horng
    Brunetto, Maurizia
    Buti, Maria
    SWISS MEDICAL WEEKLY, 2018, 148 : 26S - 26S
  • [9] 48-WEEK SAFETY AND EFFICACY OF SWITCHING TO TENOFOVIR ALAFENAMIDE (TAF) FROM TENOFOVIR DISOPROXIL FUMARATE (TDF) IN CHRONIC HBV ASIAN PATIENTS WITH TDF RISK FACTORS (RF)
    Ahn, Sang Hoon
    Kao, Jia-Horng
    Hann, Hie-Won
    Scott, Fung
    Trinh, Huy
    Nguyen, Tuan Trong
    Paik, Seung Woon
    Gaggar, Anuj
    Flaherty, John
    Yee, Leland
    Jump, Belinda
    Sethi, Shalini
    Wu, George
    Chan, Carol Yee Kwan
    GUT, 2020, 69 : A73 - A74
  • [10] BONE AND RENAL SAFETY OF TENOFOVIR ALAFENAMIDE ( TAF) AT 8 YEARS IN CHRONIC HBV ( CHB) PATIENTS WITH UNDERLYING RISK FACTORS FOR USE OF TENOFOVIR DISOPROXIL FUMARATE ( TDF)
    Buti, Maria
    Gane, Edward J.
    Agarwal, Kosh
    Wong, Grace Lai-Hung C.
    Lim, Young-Suk
    Chen, Chi-Yi
    Lim, Seng Gee
    Yatsuhashi, Hiroshi
    Fung, Scott K.
    Abramov, Frida
    Wang, Hongyuan
    Yee, Leland J.
    Flaherty, John F.
    Pan, Calvin Q.
    Marcellin, Patrick
    HEPATOLOGY, 2023, 78 : S507 - S509
12345